CA2382404C - Tricyclic inhibitors of poly(adp-ribose) polymerases - Google Patents

Tricyclic inhibitors of poly(adp-ribose) polymerases Download PDF

Info

Publication number
CA2382404C
CA2382404C CA002382404A CA2382404A CA2382404C CA 2382404 C CA2382404 C CA 2382404C CA 002382404 A CA002382404 A CA 002382404A CA 2382404 A CA2382404 A CA 2382404A CA 2382404 C CA2382404 C CA 2382404C
Authority
CA
Canada
Prior art keywords
alkyl
aryl
cycloalkyl
heterocycloalkyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002382404A
Other languages
English (en)
French (fr)
Other versions
CA2382404A1 (en
Inventor
Stephen Evan Webber
Donald James Skalitzky
Jayashree Girish Tikhe
Robert Arnold Kumpf
Joseph Timothy Marakovits
Walter Brian Eastman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Agouron Pharmaceuticals LLC
Original Assignee
Cancer Research Technology Ltd
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, Agouron Pharmaceuticals LLC filed Critical Cancer Research Technology Ltd
Publication of CA2382404A1 publication Critical patent/CA2382404A1/en
Application granted granted Critical
Publication of CA2382404C publication Critical patent/CA2382404C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002382404A 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose) polymerases Expired - Fee Related CA2382404C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15214299P 1999-08-31 1999-08-31
US60/152,142 1999-08-31
PCT/US2000/023882 WO2001016136A2 (en) 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose) polymerases

Publications (2)

Publication Number Publication Date
CA2382404A1 CA2382404A1 (en) 2001-03-08
CA2382404C true CA2382404C (en) 2009-03-24

Family

ID=22541675

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002382404A Expired - Fee Related CA2382404C (en) 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose) polymerases

Country Status (48)

Country Link
US (1) US6548494B1 (enExample)
EP (1) EP1208104B1 (enExample)
JP (1) JP4272375B2 (enExample)
KR (1) KR20020038742A (enExample)
CN (1) CN1384835A (enExample)
AP (1) AP1553A (enExample)
AR (1) AR035162A1 (enExample)
AT (1) ATE287406T1 (enExample)
AU (1) AU781826B2 (enExample)
BG (1) BG106562A (enExample)
BR (1) BR0015051A (enExample)
CA (1) CA2382404C (enExample)
CO (1) CO5200769A1 (enExample)
CR (1) CR6577A (enExample)
CZ (1) CZ2002613A3 (enExample)
DE (1) DE60017575T2 (enExample)
DK (1) DK1208104T3 (enExample)
DO (1) DOP2000000069A (enExample)
DZ (1) DZ3216A1 (enExample)
EA (1) EA200200306A1 (enExample)
EC (1) ECSP003637A (enExample)
EE (1) EE200200100A (enExample)
ES (1) ES2234657T3 (enExample)
GE (1) GEP20043268B (enExample)
GT (1) GT200000145A (enExample)
HK (1) HK1045509B (enExample)
HR (1) HRP20020271A2 (enExample)
HU (1) HUP0202703A3 (enExample)
IL (1) IL147863A0 (enExample)
IS (1) IS6289A (enExample)
MA (1) MA25876A1 (enExample)
MX (1) MXPA02002138A (enExample)
MY (1) MY135910A (enExample)
NO (1) NO322475B1 (enExample)
NZ (1) NZ516793A (enExample)
OA (1) OA12016A (enExample)
PA (1) PA8501801A1 (enExample)
PE (1) PE20010538A1 (enExample)
PL (1) PL354242A1 (enExample)
PT (1) PT1208104E (enExample)
SI (1) SI1208104T1 (enExample)
SK (1) SK2592002A3 (enExample)
SV (1) SV2003000162A (enExample)
UA (1) UA73144C2 (enExample)
UY (1) UY26323A1 (enExample)
WO (1) WO2001016136A2 (enExample)
YU (1) YU15102A (enExample)
ZA (1) ZA200200830B (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
PL347885A1 (en) * 1999-09-28 2002-04-22 Basf Ag Azepinoindole derivatives, the production and use thereof
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
WO2003051879A1 (en) * 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
JP4500161B2 (ja) 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
WO2003103666A2 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
EP1947102A1 (en) 2003-01-09 2008-07-23 Pfizer, Inc. Compositions comprising diazepinoindole derivatives as kinase inhibitors
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
BRPI0412899B1 (pt) * 2003-07-25 2021-10-05 Cancer Research Technology Limited Uso de um composto ou um sal farmaceuticamente aceitável do mesmo para a manufatura de um medicamento citotóxico para o tratamento de câncer de ovário, câncer de mama, câncer de próstata ou câncer pancreático
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
EP1684736B1 (en) 2003-12-01 2011-08-24 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
KR100876520B1 (ko) * 2004-09-22 2008-12-31 화이자 인코포레이티드 폴리(ａｄｐ-리보오스) 폴리머라제 억제제의 제조 방법
CN101223175B (zh) * 2005-01-19 2013-03-27 卫材有限公司 二氮杂苯并[de]蒽-3-酮化合物及抑制PARP的方法
CA2609562A1 (en) 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
WO2006137510A1 (ja) * 2005-06-24 2006-12-28 Ono Pharmaceutical Co., Ltd. 脳血管障害時における出血低減剤
CN102335163A (zh) * 2005-07-18 2012-02-01 彼帕科学公司 癌症的治疗
JP2009503069A (ja) * 2005-08-05 2009-01-29 アストラゼネカ アクチボラグ 三環式ベンゾイミダゾール類、および代謝性グルタミン酸塩受容体のモジュレータとしてのそれらの使用
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
EP2038654A4 (en) * 2006-06-12 2010-08-11 Bipar Sciences Inc METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
JP2010502731A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
KR20100038295A (ko) 2007-06-05 2010-04-14 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 피질 카테콜아민성 신경 전달의 조정자로서의 이치환된 페닐피롤리딘
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
EP2188278A1 (en) 2007-09-14 2010-05-26 AstraZeneca AB Phthalazinone derivatives
AU2008321128A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
SG185954A1 (en) * 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
US20090149397A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
JP2011521618A (ja) * 2008-02-04 2011-07-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ仲介疾患を診断および治療する方法
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2011003740A (es) 2008-10-07 2011-05-02 Astrazeneca Uk Ltd Formulacion farmaceutica - 514.
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
US20150218110A1 (en) * 2012-09-05 2015-08-06 Bayer Cropscience Ag Use of substituted benzodiazepinones and benzazepinones or the salts thereof as active substances against abiotic plant stress
ES2700348T3 (es) * 2014-01-05 2019-02-15 Univ Washington Trazadores radioetiquetados para poli (ADP-ribosa) polimerasa-1 (PARP-1), métodos y usos para estos
EP3325623B3 (en) 2015-07-23 2021-01-20 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
SG11201903842YA (en) 2016-11-02 2019-05-30 Immunogen Inc Combination treatment with antibody-drug conjugates and parp inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
EP3615026B1 (en) 2017-04-28 2021-03-03 Akribes Biomedical GmbH A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
US11535633B2 (en) 2018-06-28 2022-12-27 Jiangsu Hengrui Medicine Co., Ltd. Fused tricyclic heterocycle compounds and therapeutic uses thereof
CN112552314B (zh) * 2018-08-24 2022-03-04 杭州阿诺生物医药科技有限公司 Sting激动剂小分子抗肿瘤化合物及其应用
WO2020124059A1 (en) * 2018-12-14 2020-06-18 Eternity Bioscience Inc. Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof
CN116804019A (zh) * 2019-02-02 2023-09-26 正大天晴药业集团股份有限公司 用于parp抑制剂的吲哚并七元酰肟类似物
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
CN114341162B (zh) 2019-07-10 2025-10-17 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230234938A1 (en) 2020-04-28 2023-07-27 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
EP4274905A1 (en) 2021-01-08 2023-11-15 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
IL307339A (en) 2021-04-08 2023-11-01 Rhizen Pharmaceuticals Ag Poly(ADP-ribose) polymerase inhibitors
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
WO2025106920A1 (en) * 2023-11-15 2025-05-22 Yale University Parp pet imaging agents and methods of using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004771A1 (en) * 1995-08-02 1997-02-13 Newcastle University Ventures Limited Benzimidazole compounds
GB1052390A (enExample) 1964-03-24
US3642820A (en) * 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
US3734919A (en) * 1969-11-03 1973-05-22 Upjohn Co 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones
DE2056215A1 (de) 1970-11-16 1972-05-18 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE4125292A1 (de) 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
AU674613B2 (en) 1993-09-28 1997-01-02 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
CN1198614C (zh) 1997-05-13 2005-04-27 奥科特默股份有限公司 pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法
AU9298198A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
EP1077944A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity

Also Published As

Publication number Publication date
ATE287406T1 (de) 2005-02-15
NO20020421L (no) 2002-04-25
BR0015051A (pt) 2002-06-25
AP1553A (en) 2006-01-18
ECSP003637A (es) 2002-03-25
EE200200100A (et) 2003-06-16
MY135910A (en) 2008-07-31
YU15102A (sh) 2004-12-31
EP1208104B1 (en) 2005-01-19
ES2234657T3 (es) 2005-07-01
PE20010538A1 (es) 2001-05-22
MA25876A1 (fr) 2003-10-01
JP2003513015A (ja) 2003-04-08
IS6289A (is) 2002-02-27
SI1208104T1 (en) 2005-06-30
AU7338900A (en) 2001-03-26
UY26323A1 (es) 2001-04-30
IL147863A0 (en) 2002-08-14
ZA200200830B (en) 2003-03-26
EP1208104A2 (en) 2002-05-29
BG106562A (bg) 2003-03-31
HK1045509B (en) 2005-04-29
WO2001016136B1 (en) 2001-11-15
GT200000145A (es) 2002-02-21
PL354242A1 (en) 2003-12-29
AU781826B2 (en) 2005-06-16
AR035162A1 (es) 2004-05-05
JP4272375B2 (ja) 2009-06-03
WO2001016136A3 (en) 2001-06-21
DE60017575D1 (de) 2005-02-24
CO5200769A1 (es) 2002-09-27
CZ2002613A3 (cs) 2002-08-14
HUP0202703A2 (hu) 2002-12-28
MXPA02002138A (es) 2003-08-20
NO20020421D0 (no) 2002-01-28
OA12016A (en) 2006-04-19
SV2003000162A (es) 2003-07-29
UA73144C2 (en) 2005-06-15
HUP0202703A3 (en) 2004-12-28
HK1045509A1 (en) 2002-11-29
KR20020038742A (ko) 2002-05-23
US6548494B1 (en) 2003-04-15
WO2001016136A2 (en) 2001-03-08
SK2592002A3 (en) 2002-10-08
PT1208104E (pt) 2005-04-29
NO322475B1 (no) 2006-10-09
EA200200306A1 (ru) 2002-08-29
CR6577A (es) 2003-12-05
DOP2000000069A (es) 2002-08-30
CA2382404A1 (en) 2001-03-08
DE60017575T2 (de) 2005-06-09
GEP20043268B (en) 2004-06-25
DZ3216A1 (fr) 2001-03-08
PA8501801A1 (es) 2002-08-26
NZ516793A (en) 2004-03-26
DK1208104T3 (da) 2005-05-02
HRP20020271A2 (en) 2005-12-31
CN1384835A (zh) 2002-12-11

Similar Documents

Publication Publication Date Title
CA2382404C (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
EP2350081B1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
AU2004203977B2 (en) Diazepinoindole derivatives as kinase inhibitors
AU2004260738B2 (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
WO2003106430A1 (en) Benzimidazole inhibitors of poly(adp-ribosyl) polymerase
JP2012514044A (ja) Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
EP3231798A1 (en) Thiazole intermediates useful in the preparation of raf kinase inhibitors
CA2694284A1 (en) Heterocyclic compounds useful as raf kinase inhibitors
RO121778B1 (ro) Inhibitori triciclici de poli(adp-riboza) polimerază
CN101883772A (zh) 三唑并吡啶11β-羟基类固醇I型脱氢酶抑制剂
CN115611898A (zh) 四环类衍生物、其制备方法及其在医药上的应用
CN105073751A (zh) 作为酪蛋白激酶1δ/ε抑制剂的新的取代的咪唑
CA2443567A1 (en) Novel tricyclic pyridyl benzazepine carboxamides and derivatives thereofas tocolytic oxytocin receptor antagonists
WO2021247971A1 (en) Inhibitors of fibroblast growth factor receptor kinases
TW202039491A (zh) 鹵代烯丙基胺類化合物及其用途
JP2002501067A (ja) Ｇａｂａ受容体に対するリガンドとしてのトリアゾロ−ピリダジン誘導体
CZ139298A3 (cs) Amidinové a isothiomočovinové deriváty jako inhibitory synthasy oxidu dusičného
JP2022548381A (ja) 置換ベンゾイミダゾールカルボキサミドおよび医学的障害の治療におけるこれらの使用
TW202345806A (zh) 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
EP3915990A1 (en) 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer
HK1154002B (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170831